Besides an introduction by Lalitha K. Shankar and Daniel C. Sullivan of the Cancer Imaging Program at the National Cancer Institute, the JNM supplement includes seven articles from practitioners in the United States and abroad. The articles cover topics such as PET/CT’s accuracy over CT alone in staging and response assessment; the use of PET/CT for cancer screening; a practical set of guidelines and algorithms for the use of 18F-FDG PET/CT in the evaluation and management of head and neck cancer and thyroid cancer; and how PET/CT could make a difference in drug development and clinical management for patients.

Articles include


* “Integrating PET and PET/CT into the Risk-Adapted Therapy of Lymphoma,” Yvette L. Kasamon, oncology and medicine departments; Richard J. Jones, oncology department; and Richard L. Wahl, oncology department and Division of Nuclear Medicine at the Russell H. Morgan Department of Radiology and Radiological Science, all at Johns Hopkins Medical Institutions, Baltimore, Md.
* “Can PET/CT Replace Separate Diagnostic CT for Cancer Imaging? Optimizing CT Protocols for Imaging Cancers of the Chest and Abdomen,” Hilmar Kuehl, Patrick Veit and Gerald Antoch, Department of Diagnostic and Interventional Radiology and Neuroradiology, and Sandra J. Rosenbaum and Andreas Bockisch, Department of Nuclear Medicine, all at the University Hospital Essen, Essen, Germany.
* “Early Detection of Cancer Recurrence: 18F-FDG PET/CT Can Make a Difference in Diagnosis and Patient Care,” Ora Israel, Department of Nuclear Medicine, Rambam Health Care Campus, and B. Rappaport School of Medicine, Technion–Israel Institute of Technolog; and Abraham Kuten, B. Rappaport School of Medicine, Technion–Israel Institute of Technology, and Department of Oncology, Rambam Health Care Campus, both in Haifa, Israel.
* “Screening for Cancer With PET and PET/CT: Potential and Limitations,” Heiko Schöder, Department of Radiology/Nuclear Medicine, and Mithat Gönen, Department of Biostatistics and Epidemiology, both at Memorial Sloan-Kettering Cancer Center, New York, N.Y.
* “Monitoring Cancer Treatment With PET/CT: Does It Make a Difference?” Wolfgang A. Weber, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, and Robert Figlin, Division of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Los Angeles, Calif.
* “PET-Based Treatment Planning in Radiotherapy: A New Standard?” Vincent Grégoire, the Radiation Oncology Department and the Center for Molecular Imaging and Experimental Radiotherapy, Xavier Geets, Center for Molecular Imaging and Experimental Radiotherapy and Max Lonneux, Center for Molecular Imaging and Experimental Radiotherapy and Nuclear Medicine Department, all at Université Catholique de Louvain, St. Luc University Hospital in Brussels, Belgium; and Karin Haustermans and Sarah Roels, both at the Radiation Oncology Department, Katholiek Universiteit Leuven, Gasthuisberg University Hospital, Leuven, Belgium.

More Industry Headlines